Research portfolio update
ARQ-550RP
ARQ-501 related compound designed to be orally available, with composition of matter IP
ARQ-650RP
Non-E2F program, designed to selectively induce cancer cell death.
Current lead compound ARQ-707 has demonstrated potent anti-tumor activity against human breast cancer in mouse model.
Selection of clinical candidate targeted by Q1, 2005.